Research
Our team is committed to developing research and participating as a research site for clinical trials for various movement disorders. Some of our current and past clinical trials include:
Registry of Deep Brain Stimulation with the VERCISE™ System: Vercise™ DBS Registry.
A Randomized, placebo-controlled, double-blind study to evaluate the effect of SAGE-718 on cognitive function in participants with Huntington’s disease.
A Phase 3, multicenter, open-label safety study to evaluate the long-term safety and tolerability of SAGE-718 in participants with Huntington’s disease.
A Phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of valbenazine for the treatment of chorea associated with Huntington’s disease.
Open-label rollover study for continuing valbenazine administration for the treatment of chorea associated with Huntington disease.
A double-blind, placebo-controlled, randomized, 18-month phase 2A study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of oral UCB0599 in study participants with early Parkinson’s disease.
A dose-blinded extension study to evaluate the long-term efficacy, safety, safety and tolerability of UCB0599 in study participants with Parkinson’s disease.
Effects of lithium therapy on blood-based therapeutic targets in Parkinson’s disease.
Effects of lithium therapy on blood-based therapeutic targets in Parkinson’s disease: treatment discontinuation/extension sub-study.
A Phase 3, twelve-week, multi-center, multinational, randomized, double-blind, double-dummy, parallel group study to determine the efficacy, safety and tolerability of P2B001 once daily compared to its individual components in subjects with early Parkinson’s disease and to a calibration arm of pramipexole ER.
A multicenter, randomized, double-blind, placebo-controlled study, with an active-treatment dose-blinded period, to evaluate the safety, pharmacokinetics, and pharmacodynamics of BIIB054 in subjects with Parkinson’s disease.